Organ chips and computational models have won FDA and NIH policy openings, but validation costs and research culture still slow adoption
This article traces how animal-testing alternatives known as NAMs—organ chips, organoids and computational simulations—moved from a lung-on-a-chip paper that Science asked to be backed up with mouse experiments, to the 2022 FDA Modernization Act 2.0 authorizing NAMs in preclinical studies, a 2025 FDA pledge to make animal studies the exception, and a September 2026 rule that would replace "animal tests" with "nonclinical tests" in drug regulations, while identifying validation standardization, the high cost of head-to-head comparisons and research-culture inertia as the main bottlenecks.